NovaSeq 6000 Sequencing System
NovaSeq 6000 测序系统
基本信息
- 批准号:10431038
- 负责人:
- 金额:$ 94.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-01 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAlabamaAwardBase SequenceBiological AssayCancer BiologyCardiac developmentComprehensive Cancer CenterCost SavingsDNA SequenceDataEcologyEpigenetic ProcessFacultyFundingGenomicsGenomics Shared ResourceHigh-Throughput Nucleotide SequencingImmunologyInstitutionMetagenomicsNephrologyNeurobiologyOutputPriceProcessResearchResearch PersonnelResearch SupportResourcesRunningSamplingSchoolsSequence AnalysisServicesSkeletal DevelopmentStructureSystemTechnologyTimeUnited States National Institutes of HealthUniversitiesciliopathycostdata acquisitionexpectationexperimental studygenetic technologyinstrumentmedical schoolssingle cell sequencingtumor immunologyundergraduate student
项目摘要
Title: NovaSeq6000 High-Throughput DNA Sequencer
Project Summary/Abstract.
The UAB Genomics Core is requesting funds to purchase an Illumina NovaSeq6000 NextGeneration
DNA sequencer to align the increased demand for sequencing and expectations of increased data output at
low cost of the core’s users with the appropriate technology. The NovaSeq6000 (NovaSeq) is currently the
highest throughput sequencing instrument on the market and can produce up to 6 trillion bases of sequence
from one instrument run. The advantages of the NovaSeq to our NIH funded investigators are 1) access to
state-of-the-art sequencing technology, 2) ability to perform experiments prohibited with the core’s current
instruments, 3) significant cost savings, 4) reduction in experimental bias in terms of batch effect, and 5)
decreased times for data acquisition. The Genomics Core is the only genomics core on the UAB campus
and serves the medical school, graduate school, undergraduate campus, and is the Comprehensive
Genomics Shared Resource within the O’Neal Comprehensive Cancer Center structure. The core currently
processes samples for various high throughput sequencing assays on a NextSeq500 and a MiSeq.
Increased demand for sequencing from multiple UAB investigators combined with the requirement of
increased sequencing depth make our NextSeq system near obsolete. Since its inception 20 years ago, the
Genomics Core has dedicated its resources to providing advanced technologies for genetic and genomic
research. The core has supported 188 faculty from across campus, 86 with NIH awards. Moreover, the core
has supported various investigators at neighboring institutions such as University of South Alabama,
Alabama State University, and Emory University. The research supported by the core is incredibly diverse
and includes cancer biology, nephrology, immunology, cancer immunology, ecology, cardiac development,
ciliopathies, skeletal development, neurobiology, bacterial-host interactions, metagenomics, SARS-CoV-2
sequence analysis, epigenetics and single cell sequencing analysis. The addition of the NovaSeq to the UAB
Genomics Core will allow us the ability to provide investigators with the sequencing capacity they demand at
a price point they expect and will allow the core to expand services.
标题:NovaSeq6000 高通量 DNA 测序仪
项目摘要/摘要。
UAB Genomics Core 正在申请资金购买 Illumina NovaSeq6000 NextGeneration
DNA 测序仪可满足日益增长的测序需求和增加数据输出的期望
NovaSeq6000(NovaSeq)是目前使用适当技术的核心用户的低成本。
市场上通量最高的测序仪器,可产生高达 6 万亿个碱基的序列
对于我们 NIH 资助的研究人员来说,NovaSeq 的优势在于:1) 可以通过一台仪器运行
最先进的测序技术,2) 能够执行核心电流禁止的实验
仪器,3) 显着节省成本,4) 减少批次效应方面的实验偏差,以及 5)
减少数据采集时间。 Genomics Core 是 UAB 校园内唯一的基因组学核心。
服务于医学院、研究生院、本科生校园,是综合性的
奥尼尔综合癌症中心结构内的基因组共享资源目前是核心。
在 NextSeq500 和 MiSeq 上处理用于各种高通量测序测定的样品。
多个 UAB 研究人员对测序的需求增加,以及
测序深度的增加使得我们的 NextSeq 系统自 20 年前诞生以来几乎已经过时。
Genomics Core 致力于提供先进的遗传和基因组技术
该核心支持了来自整个校园的 188 名教职人员,其中 86 名获得了 NIH 奖项。
支持南阿拉巴马大学等邻近机构的各种研究人员,
阿拉巴马州立大学和埃默里大学的核心支持的研究非常多样化。
包括癌症生物学、肾病学、免疫学、癌症免疫学、生态学、心脏发育、
纤毛病、骨骼发育、神经生物学、细菌-宿主相互作用、宏基因组学、SARS-CoV-2
序列分析、表观遗传学和单细胞测序分析 将 NovaSeq 添加到 UAB 中。
Genomics Core 将使我们能够为研究人员提供他们所需的测序能力
他们期望的价格点并将允许核心扩展服务。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL R CROWLEY其他文献
MICHAEL R CROWLEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL R CROWLEY', 18)}}的其他基金
相似海外基金
Talking Circle for Native American Youth Living Well (A Yo Li)
美国原住民青年美好生活谈话圈(A Yo Li)
- 批准号:
10739361 - 财政年份:2023
- 资助金额:
$ 94.51万 - 项目类别:
Wake Forest NeuroNext Clinical Site (WAKENN)
维克森林 NeuroNext 临床站点 (WAKENN)
- 批准号:
10744928 - 财政年份:2023
- 资助金额:
$ 94.51万 - 项目类别:
Deep South KUH Premier Research and Inter-disciplinary Mentored Education (PRIME)
深南 KUH 顶级研究和跨学科指导教育 (PRIME)
- 批准号:
10724926 - 财政年份:2023
- 资助金额:
$ 94.51万 - 项目类别:
Multisite Implementation of COMPRENDO (ChildhOod Malignancy Peer REsearch NavigatiOn) to improve participation of Hispanic children in cancer clinical trials
多站点实施 COMPRENDO(儿童恶性肿瘤同行研究导航)以提高西班牙裔儿童对癌症临床试验的参与
- 批准号:
10639968 - 财政年份:2023
- 资助金额:
$ 94.51万 - 项目类别: